Enovis bids 155m euros for a French surgical robotics maker

Enovis signed a binding offer on 1 September 2026 to acquire eCential Robotics, a French company that builds robotic systems for bone surgery. The upfront enterprise value is 155m euros, with cash consideration to shareholders of roughly 176m euros and up to 35m euros more contingent on milestones. Enovis expects to close by the end of 2026, subject to regulatory approvals.

eCential’s platform puts 2D and 3D imaging, real-time navigation and robotics into a single open system for bone procedures. Enovis already sells ARVIS, an augmented-reality system that overlays guidance onto the surgeon’s view, and frames the purchase as adding robotic capability to its ASTRA enabling-technology platform.

What changes hands is a category of capability rather than a product line. A navigated robotic arm does not make a surgeon steadier in any general sense. It narrows the distance between the plan drawn on a scan and the cut made in the bone, which is where a large share of surgical error actually lives. Whether narrowing it far enough changes patient outcomes is the argument this field has been having for a decade, and a purchase does not settle it.

eCential’s Perla TL clearance with Spineart is covered in its own pulse. This is the company changing owner, not the device changing status.